Work

Targeted Alpha-particle Nano-generator Actinium-225 (225Ac)-lintuzumab (anti-CD33) in Acute Myeloid Leukemia (AML)

Year: 2013

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2013.07.088

Authors: J.G. Jurcic, T.L. Rosenblat, M.R. McDevitt, N. Pandit-Taskar, J.A. Carrasquillo, S.M. Chanel, K. Zikaras, M.G. Frattini, P.M. Maslak, D. Cicic, S.M. Larson, D.A. Scheinberg

Institutions: Memorial Sloan Kettering Cancer Center, Actinium Pharmaceuticals (United States)

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2123790660

FWCI:

Cites:

Cited by: 13

Related to: 10